Department of Obstetrics & Gynaecology, Skåne University Hospital, Lund University, Lund.
Department of Clinical Genetics and Pathology, Office for Medical Services, Region Skåne.
Eur J Cancer Prev. 2021 Jul 1;30(4):334-340. doi: 10.1097/CEJ.0000000000000693.
HPV self-sampling is an option for cervical screening. The aim of this randomised study was to investigate the compliance, prevalence of HPV, and prevalence of severe dysplasia in a vaginal self-sampling group in comparison to cervical samples collected by midwives (control arm). The hypothesis was that there would be no difference between vaginal self-sampling and cervical sampling to find high-grade cervical dysplasia or cancer.
Vaginal HPV self-sampling kits were sent by regular mail to 14 765 randomly selected women aged 30-64 years old in the screening programme. HPV-positive women were invited for a follow-up examination by their midwife in which they provided a cervical sample for cytological and HPV co-testing. The control arm consisted of 14 839 women who met the same inclusion criteria and were invited to have cervical sampling by midwives for primary HPV screening. All HPV samples were analysed by the Aptima HPV assay (Hologic Inc.).
The participation rate was 33.5% in the self-sampling arm and 47.5% in the cervical sampling arm, (P < 0.0001). HPV was detected in 17.1% (95% confidence interval (CI), 16.1-18.23%) in the self-sampling arm and 4.5% (95% CI, 4.0-5.0%) in the cervical sampling arm. Histological, severe dysplasia was observed among 0.48% (95% CI, 0.3-0.72%) and 0.47% (95% CI, 0.3-0.66%) of the self-sampling and the cervical sampling groups, respectively.
The self-sampling approach detects a similar proportion of severe dysplasia as regular screening. Thus, our study indicates that self-sampling could replace primary HPV screening of cervical samples.
HPV 自我采样是宫颈癌筛查的一种选择。本随机研究的目的是调查阴道自我采样组与由助产士采集的宫颈样本(对照组)相比,其依从性、HPV 流行率和重度发育不良流行率。假设是阴道自我采样与宫颈采样在发现高级别宫颈发育不良或癌症方面没有差异。
通过普通邮件向 14765 名年龄在 30-64 岁的筛查计划中随机选择的女性发送阴道 HPV 自我采样试剂盒。HPV 阳性女性被邀请由其助产士进行随访检查,她们提供宫颈样本进行细胞学和 HPV 联合检测。对照组由 14839 名符合相同纳入标准并被邀请由助产士进行宫颈采样进行原发性 HPV 筛查的女性组成。所有 HPV 样本均采用 Aptima HPV 检测法(Hologic Inc.)进行分析。
自我采样组的参与率为 33.5%,宫颈采样组的参与率为 47.5%(P<0.0001)。自我采样组 HPV 检出率为 17.1%(95%置信区间(CI),16.1-18.23%),宫颈采样组为 4.5%(95%CI,4.0-5.0%)。在自我采样组和宫颈采样组中,分别有 0.48%(95%CI,0.3-0.72%)和 0.47%(95%CI,0.3-0.66%)观察到组织学重度发育不良。
自我采样方法检测到的重度发育不良比例与常规筛查相似。因此,我们的研究表明,自我采样可以替代宫颈样本的原发性 HPV 筛查。